Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03329014
Other study ID # CNS7056-019
Secondary ID
Status Completed
Phase Phase 1
First received
Last updated
Start date May 15, 2017
Est. completion date June 14, 2017

Study information

Verified date April 2019
Source Paion UK Ltd.
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

A prospective dose escalation, nine period cross-over trial assessing the safety, pharmacokinetics, bioavailability and pharmacodynamics of escalating doses of Remimazolam when administered intranasally as powder and solution in healthy subjects and compared to an intravenous control


Description:

The design will be a randomized, double-blind, comparative, placebo- and active-controlled nine-period crossover study in healthy male volunteers. Subjects will be randomized and will receive each of the 9 treatments which will be separated by a minimum of 48 hours.The first treatment arm will always be the intravenous remimazolam. Eligible subjects will then be randomized to treatment sequence prior to study drug administration in treatment period 2. Each subject will participate in the study for up to 51 days, from Screening until Follow-up.


Recruitment information / eligibility

Status Completed
Enrollment 12
Est. completion date June 14, 2017
Est. primary completion date June 9, 2017
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Male
Age group 18 Years to 45 Years
Eligibility Inclusion Criteria:

1. Willing to participate in the trial, give written informed consent prior to the initiation of any protocol specific procedures, and to comply with the study restrictions.

2. Able to speak, read and understand English sufficiently to allow completion of all study assessments.

3. Gender: males

4. Age: 18 45 years, inclusive, at screening

5. Weight: 50 to 120 kg, inclusive, at screening

6. Body mass index: 19.0 to 33.0 kg/m2, inclusive, at screening

7. Healthy status, defined by the absence of evidence of any clinically significant, active or chronic diseases, in the opinion of the Investigator, following a detailed medical and surgical history, a complete physical examination, and evaluation of vital signs, 12 lead ECG, hematology, blood chemistry, serology, and urinalysis.

8. Previous experience with intranasal drug application (within the last year)

9. Ability and willingness to abstain from alcohol, caffeine, and xanthine containing beverages or food (e.g., coffee, tea, cola, chocolate, energy drinks) from 24 hours (1 day) prior to admission to the clinical facility on Day 0 until study discharge.

10. All values for hematology and for clinical chemistry tests of blood and urine within the normal range or showing no clinically relevant deviations as judged by the Investigator.

Exclusion Criteria:

1. Use of any intranasally applied medication within two weeks from randomization.

2. Use of benzodiazepines or other central nervous system (CNS) active drugs within 4 weeks of inclusion.

3. History of alcohol abuse or drug addiction (except nicotine), as defined by the Diagnostic and Statistical Manual of Mental Disorders, fifth edition, text revision (DSM V TR), or any self reported dependence or "addiction" within the subject's lifetime (except nicotine or caffeine).

4. Abnormal 12 lead ECG at screening, including:

1. QTcF = 450 ms

2. QRS = 110 ms

3. PR = 220 ms

4. Second or third degree AV block

5. Use of any investigational drug or device within 30 days of the first dose of study medication.

6. History of relevant food allergies.

7. Any disease which, in the opinion of the Investigator, poses an unacceptable risk to the subjects.

8. Known allergy, hypersensitivity or prior intolerance to benzodiazepine derivatives or flumazenil, or a medical condition such that these agents are contraindicated.

9. Strenuous activity, sunbathing, and contact sports within 48 hours (2 days) prior to (first) admission to the clinical facility and for the duration of the study.

10. History of donation or loss of more than 450 mL of blood or blood products within 60 days prior to dosing in the clinical research center or planned donation before 30 days has elapsed since intake of study drug in the current study.

11. Positive screening test for hepatitis B surface antigen (HBsAg), anti hepatitis C virus (HCV) antibodies, or anti human immunodeficiency virus (HIV) 1 and 2 antibodies.

12. Positive drug and alcohol screen (opiates, methadone, cocaine, amphetamines [including ecstasy], barbiturates, benzodiazepines, tricyclic antidepressants and alcohol) at screening and at admission to the clinical research center; subjects positive for cannabinoids will be allowed only at the discretion of the Investigator.

13. Inability to be venipunctured or tolerate venous access as determined by the Investigator.

14. History of clinically significant, non remote suicidal ideations or suicide attempts based on the C SSRS that, in the opinion of the Investigator, pose an unacceptable risk to the subject for participating in the study.

15. Had had any major surgery within 4 weeks of study drug administration.

16. Requires concomitant treatment with any prescription or non prescription medications (with the exception of acetaminophen) or natural health products (herbal remedies), or respiratory depressants, or cannot safely discontinue these medications at least 7 days prior to receiving study drug.

17. Subject is an employee of the sponsor or research site personnel directly affiliated with this study or their immediate family member defined as a spouse, parent, child or sibling, whether biological or legally adopted.

18. A subject who, in the opinion of the investigator, is considered unsuitable or unlikely to comply with the study protocol for any reason.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Remimazolam
For induction and maintenance of sedation
Placebo
Control arm

Locations

Country Name City State
United States PRA Health Sciences Salt Lake City Utah

Sponsors (2)

Lead Sponsor Collaborator
Paion UK Ltd. PRA Health Sciences

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Number of Participants with Treatment-related Adverse Events Adverse events assessment will include: change in clinical laboratory assessments from baseline, change in vital signs from baseline, change in 12-lead electrocardiograms from baseline, drop in oxygen saturation measured using continuous pulse oximetry, nasal effect using the Nasal Effect Questionnaire (NEQ) and nose and throat examination. Adverse events with a respiratory or cardiovascular focus and adverse events related to effects seen with medications known to be associated with abuse will be analysed separately. The intensity, causality, outcome, seriousness and expectedness of adverse events will be assessed Predose until 180 minutes postdose
Secondary Alertness/Drowsiness using a bipolar 100-point Visual Analogue Scale (VAS) maximum effect (Emax), time to Emax (TEmax), minimum effect (Emin) and area under the effect curve (AUEC) determined pre-dose, 5, 10, 30, 60 and 180 minutes post dose Predose until 180 minutes postdose
Secondary Agitation/Relaxation using a bipolar 100-point Visual Analogue Scale (VAS) maximum effect (Emax), time to Emax (TEmax), minimum effect (Emin) and area under the effect curve (AUEC) determined pre-dose, 5, 10, 30, 60 and 180 minutes post dose Predose until 180 minutes postdose
Secondary Any Drug Effects using a unipolar 100-point Visual Analogue Scale (VAS) maximum effect (Emax), time to Emax (TEmax), minimum effect (Emin) and area under the effect curve (AUEC) determined pre-dose, 5, 10, 30, 60 and 180 minutes post dose Predose until 180 minutes postdose
Secondary Memory/Amnestic Effects using the Paired Associates Learning (PALs) test maximum effect (Emax), time to Emax (TEmax), minimum effect (Emin) and area under the effect curve (AUEC) determined pre-dose,10, 30, 60 and 180 minutes post dose Predose until 180 minutes postdose
Secondary Reaction Time using the Reaction Time Test maximum effect (Emax), time to Emax (TEmax), minimum effect (Emin) and area under the effect curve (AUEC) determined pre-dose, 20, 30, 60, 90, 120, 150 and 180 post dose Predose until 180 minutes postdose
Secondary Time to Maximum Observed Plasma Concentration (Tmax) From first dose of study drug until 240 minutes postdose
Secondary Maximum Observed Plasma Concentration (Cmax) From first dose of study drug until 240 minutes postdose
Secondary Area Under the Plasma Concentration-time Curve from Zero to the last Measurable Concentration (AUC0-last) From first dose of study drug until 240 minutes postdose
Secondary Area Under the Plasma Concentration-time Curve from Zero to Infinity (AUC0-8) From first dose of study drug until 240 minutes postdose
Secondary Terminal Elimination Half-life (t1/2) for Remimazolam and its Metabolite (CNS7054) From first dose of study drug until 240 minutes postdose
Secondary Concentration at Time Zero (C0) for Intravenous Remimazolam and its Metabolite (CNS7054) Only From first dose of study drug until 240 minutes postdose
Secondary The Fraction in Percent as a Measurement of the Rate and Extent to Which a Drug Reaches the Site of Action (F%) F% will be calculated for the highest dose level (40 mg) and dose-proportionality will be evaluated across the dose range of 10 - 40 mg for each formulation (powder and solution) as available. Dose proportionality is AUC0-8 and Cmax based. Bioavailability will be dose adjusted. From first dose of study drug until 240 minutes postdose
See also
  Status Clinical Trial Phase
Recruiting NCT03692390 - Virtual Reality vs. Standard-of-Care for Comfort Before and After Sedation in the Emergency Department N/A
Completed NCT02145169 - Inhaled Nitrous Oxide for the Prevention of Emergence Reaction During Ketamine Administration in Adults, a Pilot Study N/A
Recruiting NCT05595798 - EEG Spectral Pattern of Deep Sedation-induced Airway Adverse Effects
Completed NCT01260662 - Randomized Clinical Trial of Propofol, 1:1 and 4:1 Combination of Propofol and Ketamine for Procedural Sedation Phase 4
Completed NCT00784498 - Procedural Sedation Using Propofol Versus Midazolam/Ketamine in the Adult Emergency Department Phase 4
Completed NCT00327392 - A Safety Study of AQUAVAN® (Fospropofol Disodium) Injection for Sedation During Minor Surgical Procedures. Phase 2/Phase 3
Recruiting NCT04873596 - Dexmedetomidine and Midazolam Nebulization as Sedation During Cesarean Delivery in Pre-eclampsia Phase 2
Recruiting NCT06414395 - The Effects of Different Loading Doses of Dexmedetomidine on The Bispectral Index-Guided Propofol Sedation in Patients Undergoing Advanced Upper Gastrointestinal Endoscopic Procedures: A Randomized Control Study Phase 4
Recruiting NCT03860831 - Intranasal Ketamine and Midazolam Mixture for Procedural Sedation in Children With Mental Disabilities: Phase 1
Completed NCT00869440 - Dose-Finding Safety Study Evaluating Remimazolam (CNS 7056) in Patients Undergoing Diagnostic Upper GI Endoscopy Phase 2
Not yet recruiting NCT05757622 - Electroencephalogram Based Real-Time Sedation Level Prediction
Completed NCT03799783 - The Use of Dexmedetomidine for EEG Sedation in Children With Behavioural Disorders Phase 2
Completed NCT02180737 - Dexmedetomidine for Sedation During Radiological Interventional Procedures Phase 4
Not yet recruiting NCT01227174 - Safety and Efficacy of Propofol Only Sedation in Oral and Maxillofacial Surgery Phase 4
Recruiting NCT03499886 - Low-Dose Intravenous Ketamine Bolus Versus Conventional Technique Phase 2/Phase 3
Completed NCT03747432 - Comparison of Procedural Sedation With Propofol and Dexmedetomidine During Transcatheter Aortic Valve Implantation Phase 4
Recruiting NCT06203522 - Factors Associated With Successful Completion of MRI in Children Undergoing a Vigil Sedation With Dexmedetomidin
Withdrawn NCT05783492 - INK Feasibility Study Phase 3
Recruiting NCT04686448 - Ketofol Versus Fenofol as Procedural Sedation for Carpal Tunnel Release Phase 1/Phase 2
Completed NCT02955732 - Pharmacological Characteristics of Intranasally Given Dexmedetomidine in Paediatric Patients Phase 4